The positive report of verification of the degree by the DEVA is already a reality, which means that the first degree in Medicine will start next academic year 2022-2023 with 60 places. The rector of the UAL, Carmelo Rodríguez, assures that “this fulfils a historical demand that will have very positive repercussions for the University […]
Council adopts proposals aimed at securing the supply of medicines
Background With these proposals, the European Union intends to facilitate the implementation of the Protocol on Ireland/Northern Ireland on the ground, in line with the measures for Northern Ireland presented by the Commission on 13 October 2021. European Health Union: a stronger role for the European Medicines Agency About the proposals EU ambassadors today agreed on […]
European Health Union: a stronger role for the European Medicines Agency
As part of the on-going work to build a strong European Health Union, the Council has adopted the Regulation revising the mandate of the European Medicines Agency (EMA), taking an important step towards EMA’s reinforcement in crisis preparedness and management for medicinal products and medical devices. The new rules will allow the Agency to closely […]
EU-UK relations: Commission guarantees continued supply of medicines to Northern Ireland
The Commission has put forward proposals to ensure the continued long-term supply of medicines from Great Britain to Northern Ireland and to address outstanding supply concerns in Cyprus, Ireland and Malta. In the context of the Protocol on Ireland/Northern Ireland, this means that the same medicines will continue to be available in Northern Ireland at […]
Horizon Europe: Medical Technology and Devices: from Lab to Patient
Scope EU-funded early-stage Research on novel Medical Technologies and Devices is uncovering unique opportunities to benefits patients and support clinicians. Medical Technology and Devices businesses are facing long and capital-intensive product development cycles, complex regulatory procedures, slow market uptake requiring the support of key opinion leaders and intensive follow-up with early adopters. In addition to […]
H2020. Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities
A major challenge in life sciences, in particular within the medicines development process, is the scale of the investment required, the stepwise approach, very long development timelines and the successful involvement of relevant stakeholders. Certain IMI2 JU topics, launched under IMI2 JU Calls for proposals that are now closed, anticipated in their corresponding work plans […]
PhD in RNA Computational Biology, Neuroscience and Comparative Genomics
PhD position is available for a highly motivated trainee in the field of Computational Biology/ Bioinformatics at Neurotranscriptomics Laboratory within the Garvan Institute of Medical Research in Sydney. The research focuses on understanding how phenotypic complexity can arise during evolution, as well as how post-transcriptional regulation control neuronal function. The work focuses on the role […]
H2020. Behavioural Model of Factors Affecting Patient Adherence
Patient non-adherence to prescribed treatment is an issue that affects patient health outcomes and healthcare system costs worldwide. It is estimated that it contributes to 200 000 premature deaths in the EU each year, and the annual costs of avoidable hospitalisations, emergency care and adult outpatient visits are assessed at EUR 125 billion. Addressing the […]
First COVID-19 treatment recommended for EU authorization
EMA’s human medicines committee (CHMP) has recommended granting conditional marketing authorisation to Veklury (remdesivir) for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen Remdesivir is the first medicine against COVID-19 to be recommended for authorisation in the EU. Data on remdesivir were assessed in […]